GABA AND ANXIETY
Anticonvulsants are proving to have much broader utility in psychiatry and neurology than in just the treatment of seizure disorders, with the expanded indications dependent on the specific pharmacologic mechanism of action of a given anticonvulsant. 1 Increasing evidence shows dysfunction of the γ-aminobutyric acid (GABA)-ergic system to be pivotal to the pathogenesis of anxiety 2-4 ; thus, augmenting GABA neurotransmission may be expected to have anxiolytic actions. 2 
POTENTIAL ANXIOLYTIC ACTIONS OF ANTICONVULSANTS Direct GABAergic Mechanisms
An association between enhancement of GABA neurotransmission and anxiolytic actions is supported by the well-documented efficacy of benzodiazepines (also anticonvulsants) in anxiety disorders. 5 Other anticonvulsants may enhance GABA neurotransmission via other mechanisms, including selective inhibition of GABA reuptake, inhibition of the enzyme GABA transaminase (GABA-T), and increased synthesis and release of GABA secondary to inhibition of voltage-gated ion channels.
1,6,18 These actions are not only appealing as possible novel anxiolytics, but are also beginning to show anxiolytic efficacy in early trials.
Selective GABA reuptake inhibitors (SGRIs). The synaptic actions of GABA are terminated by highaffinity reuptake systems on presynaptic GABA neurons and neighboring glia and can be blocked by SGRIs such as tiagabine.
6-8 These actions are analogous to those of SSRIs (selective serotonin reuptake inhibitors) on the high-affinity reuptake system of serotonin neurons.
Four distinct genes for GABA transporters have been cloned: GAT-1, GAT-2, GAT-3, and BGT-1. 7 GAT-1 is the most abundant and may act not only to terminate GABA action by transporting GABA into presynaptic GABAergic terminals but also to influence excitatory and inhibitory transmission by modulating the spread of GABA from within the synaptic cleft to extrasynaptic receptors. 8 The precise roles of GAT-2, GAT-3, and BGT-1 have yet to be elucidated. At present, the only SGRI clinically available is tiagabine, an analog of the GABA reuptake inhibitor nipecotic acid.
6-8 Of the GABA transporters, tiagabine is the most highly selective for GAT-1. 6 Small, open-label studies 9-11 have shown that tiagabine monotherapy may improve anxiety symptoms and sleep quality in patients with generalized anxiety disorder and posttraumatic stress disorder (PTSD). Augmentation with tiagabine also improves anxiety symptoms in patients with treatment-refractory anxiety disorders, [12] [13] [14] and preliminary data are encouraging in patients with PTSD and comorbid disorders, anxiety and comorbid depression, and panic disorder with or without agoraphobia.
15-17
Selective GABA-T inhibitors. Vigabatrin is an anticonvulsant that robustly increases brain GABA levels by irreversibly inhibiting GABA-T, the enzyme responsible for the degradation of GABA. 18 Preliminary results suggest that vigabatrin may have anxiolytic activity in humans, given that 7-day vigabatrin treatment produced a marked reduction in cholecystokinintetrapeptide-induced panic in healthy volunteers. 19 Drug toxicity causing the development of visual field defects in some patients taking vigabatrin is expected to preclude availability of the drug in the United States, but develop- GAT-1, a high-affinity GABA plasma membrane transporter, is localized to neurons and astroglia in the cerebral cortex. 
Indirect GABAergic Mechanisms
Many anticonvulsants are inhibitors of voltage-gated ion channels for calcium (Ca 2+ ) and/or sodium (Na + ).
1 Whether these indirect actions are also related to putative GABAenhancing effects or any anxiolytic actions is unclear.
Valproate, carbamazepine, lamotrigine, and topiramate. These 4 anticonvulsants hypothetically have primary actions as modulators of voltage-gated Na + channels and may also possess GABAergic activity due to downstream consequences of blocking sodium channels.
1 However, a definitive association of their Na + channel blocking actions and any GABA activity remains to be proved, and these agents have only very limited data suggesting anxiolytic actions. Thus, valproate, 20 lamotrigine, 21 and topiramate 22 may possess some preliminary evidence of anxiolytic action in PTSD, and valproate 23 but not carbamazepine 24 may have some efficacy in panic disorder. The lack of more impressive anxiolytic efficacy data from these agents may be related to their lack of demonstrable robust actions on GABA.
Take-Home Points
◆ GABA is the major inhibitory neurotransmitter in the central nervous system and plays a key regulatory role in neuroanatomic circuits that hypothetically mediate fear in anxiety disorders. ◆ Numerous anticonvulsants may enhance GABA neurotransmission via several different mechanisms, including selective inhibition of GABA reuptake, inhibition of GABA transaminase, and increased synthesis and release of GABA secondary to inhibition of voltage-gated ion channels. ◆ Anticonvulsants with robust GABA-enhancing actions may eventually prove to be effective anxiolytics.
